Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

NetScientific portfolio company Vortex presents study to combine technology with impedance spectroscopy

The healthcare IP commercialisation group said the study introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells
Cells and test tubes
The study will be presented at the NanoBiotech Montreux 2018 conference in Switzerland

NetScientific PLC (LON:NSCI) said its portfolio company, Vortex BioSciences, has presented a study demonstrating how its technology can combine with impedance spectroscopy to improve the analysis of circulating tumour cells (CTCs).

The healthcare IP commercialisation group said the study, presented at the NanoBiotech Montreux 2018 conference in Switzerland, introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells isolated from blood samples.

READ: NetScientific portfolio company Vortex enters manufacturing partnership with STRATEC

The researchers believed the results of the study provided feasibility for label-free, reliable, fully-integrated cell enumeration, whilst keeping the cells collected intact for downstream transcriptomic, genomic or proteomic analysis.

Impedance spectroscopy involves applying a wave frequency to a system or surface and measuring the changes and is often used on various types of biological tissue.

Francois Martelet, chief executive of NetScientific and chairman of Vortex, said Vortex’s technology was “ready to be adopted by large pharmaceutical players” following the creation of an automated and reliable process and the signing of a manufacturing agreement with German firm STRATEC for its VTX-1 liquid biopsy platform in November.

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use